Management of toxicities from immunotherapy: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up

被引：492
作者：
Haanen, J. [1 ]
Obeid, M. [2 ,3 ,4 ]
Spain, L. [5 ,6 ,7 ]
Carbonnel, F. [8 ,9 ]
Wang, Y. [10 ]
Robert, C. [11 ,12 ]
Lyon, A. R. [13 ,14 ]
Wick, W. [15 ,16 ,17 ,18 ]
Kostine, M. [19 ]
Peters, S. [4 ]
Jordan, K. [20 ,21 ]
Larkin, J. [22 ]
机构：
[1] Netherlands Canc Inst NKI, Div Med Oncol, Amsterdam, Netherlands
[2] CHU Vaudois, Immunol & Allergy Serv, Lausanne, Switzerland
[3] CHU Vaudois, Lausanne Ctr Immunooncol Tox LCIT, Lausanne, Switzerland
[4] CHU Vaudois, Dept Oncol, Lausanne, Switzerland
[5] Peter MacCallum Canc Ctr, Med Oncol Dept, Melbourne, Vic, Australia
[6] Eastern Hlth, Dept Med Oncol, Melbourne, Vic, Australia
[7] Monash Univ, Eastern Hlth Clin Sch, Box Hill, Vic, Australia
[8] Hop Univ Bicetre, AP HP, Gastroenterol Dept, Le Kremlin Bicetre, France
[9] Univ Paris Saclay 11, Le Kremlin Bicetre, France
[10] Univ Texas MD Anderson Canc Ctr, Dept Gastroenterol Hepatol & Nutr, Houston, TX 77030 USA
[11] Gustave Roussy Canc Ctr, Dept Med, Villejuif, France
[12] Paris Saclay Univ, Villejuif, France
[13] Royal Brompton Hosp, Cardiooncol Serv, London, England
[14] Imperial Coll London, Natl Heart & Lung Inst, London, England
[15] Univ Hosp Heidelberg, Neurol Clin, Heidelberg, Germany
[16] Univ Hosp Heidelberg, Natl Ctr Tumour Dis, Heidelberg, Germany
[17] DKTK, Heidelberg, Germany
[18] DKFZ, Clin Cooperat Unit NeuroOncol, Heidelberg, Germany
[19] CHU Bordeaux, Hop Pellegrin, Dept Rheumatol, Bordeaux, France
[20] Ernst von Bergmann Hosp Potsdam, Dept Haematol Oncol & Palliat Med, Potsdam, Germany
[21] Univ Hosp Heidelberg, Dept Haematol Oncol & Rheumatol, Heidelberg, Germany
[22] Royal Marsden NHS Fdn Trust, London, England
来源：
ANNALS OF ONCOLOGY | 2022年 / 33卷 / 12期
关键词：
ESMO Clinical Practice Guideline; immunotherapy; side-effects; treatment; toxicity; IMMUNE CHECKPOINT INHIBITORS; CELL LUNG-CANCER; ADVERSE EVENTS; ENTERIC NEUROPATHY; PD-L1; INHIBITORS; IPILIMUMAB; PNEUMONITIS; MELANOMA; THERAPY; ANTI-CTLA-4;
D O I：
10.1016/j.annonc.2022.10.001
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
[No abstract available]
引用
收藏
页码：1217 / 1238
页数：22
相关论文
共 115 条
  • [31] Association Between Immune Checkpoint Inhibitors With Cardiovascular Events and Atherosclerotic Plaque
    Drobni, Zsofia D.
    Alvi, Raza M.
    Taron, Jana
    Zafar, Amna
    Murphy, Sean P.
    Rambarat, Paula K.
    Mosarla, Rayma C.
    Lee, Charlotte
    Zlotoff, Daniel A.
    Raghu, Vineet K.
    Hartmann, Sarah E.
    Gilman, Hannah K.
    Gong, Jingyi
    Zubiri, Leyre
    Sullivan, Ryan J.
    Reynolds, Kerry L.
    Mayrhofer, Thomas
    Zhang, Lili
    Hoffmann, Udo
    Neilan, Tomas G.
    [J]. CIRCULATION, 2020, 142 (24) : 2299 - 2311
  • [32] Summary of the guidelines for preventing opportunistic infections among hematopoietic stem cell transplant recipients
    Dykewicz, CA
    [J]. CLINICAL INFECTIOUS DISEASES, 2001, 33 (02) : 139 - 144
  • [33] Foreword
    Eckardt, Kai-Uwe
    Kasiske, Bertram L.
    [J]. KIDNEY INTERNATIONAL SUPPLEMENTS, 2012, 2 (01) : 7 - 7
  • [34] Alemtuzumab for Immune-Related Myocarditis Due to PD-1 Therapy
    Esfahani, Khashayar
    Buhlaiga, Najwa
    Thebault, Pamela
    Lapointe, Rejean
    Johnson, Nathalie A.
    Miller, Wilson H., Jr.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2019, 380 (24) : 2375 - 2376
  • [35] Fibrin Ring Granulomas in Checkpoint Inhibitor-induced Hepatitis
    Everett, Jamie
    Srivastava, Amitabh
    Misdraji, Joseph
    [J]. AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 2017, 41 (01) : 134 - 137
  • [36] Hypophysitis secondary to nivolumab and pembrolizumab is a clinical entity distinct from ipilimumab-associated hypophysitis
    Faje, Alexander
    Reynolds, Kerry
    Zubiri, Leyre
    Lawrence, Donald
    Coher, Justine, V
    Sullivan, Ryan J.
    Nachtigall, Lisa
    Tritos, Nicholas
    [J]. EUROPEAN JOURNAL OF ENDOCRINOLOGY, 2019, 181 (03) : 211 - 219
  • [37] Ocular adverse events with immune checkpoint inhibitors
    Fang, Tony
    Maberley, David A.
    Etminan, Mahyar
    [J]. JOURNAL OF CURRENT OPHTHALMOLOGY, 2019, 31 (03): : 319 - 322
  • [38] Immune checkpoint inhibition-related colitis: symptoms, endoscopic features, histology and response to management
    Foppen, Marnix H. Geukes
    Rozeman, Elisa A.
    van Wilpe, Sandra
    Postma, Cindy
    Snaebjornsson, Petur
    van Thienen, Johannes V.
    van Leerdam, Monique E.
    van den Heuvel, Michel
    Blank, Christian U.
    van Dieren, Jolanda
    Haanen, John B. A. G.
    [J]. ESMO OPEN, 2018, 3 (01)
  • [39] A Severe Case of Ipilimumab-Induced Guillain-Barre Syndrome Revealed by an Occlusive Enteric Neuropathy: A Differential Diagnosis for Ipilimumab-Induced Colitis
    Gaudy-Marqueste, Caroline
    Monestier, Sandrine
    Franques, Jerome
    Cantais, Emmanuel
    Richard, Marie-Aleth
    Grob, Jean-Jacques
    [J]. JOURNAL OF IMMUNOTHERAPY, 2013, 36 (01) : 77 - 78
  • [40] Immune checkpoint inhibitor-related dermatologic adverse events
    Geisler, Amaris N.
    Phillips, Gregory S.
    Barrios, Dulce M.
    Wu, Jennifer
    Leung, Donald Y. M.
    Moy, Andrea P.
    Kern, Jeffrey A.
    Lacouture, Mario E.
    [J]. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2020, 83 (05) : 1255 - 1268
12345678910